secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0000950170-25-072685
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TuHURA Q1 expenses rise; Phase 3 MCC trial and Kineta merger on track for Q2 2025
--------------------------------------------------------------------------------

- Q1 2025 R&D expenses $4.6M (up 28% YoY); G&A $2.4M (up 140% YoY); shares outstanding ~43.7M.
- Initiated Phase 1b/2a trial of IFx-Hu2.0 plus pembrolizumab in first-line Merkel cell carcinoma of unknown primary in May 2025.
- Targeting Q2 2025 close of Kineta acquisition; Phase 2 trial of VISTA mAb in NPM1-mutated AML expected Q3 2025.
- Phase 3 accelerated approval trial of IFx-Hu2.0 in advanced Merkel cell carcinoma expected to start Q2 2025 after lifting partial clinical hold.
- Appointed Dr. Bertrand Le Bourdonnec as EVP Head of Drug Discovery in April 2025; Dr. Craig Tendler joined Board in March 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017025072685/0000950170-25-072685-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017025072685/hura-20250515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-072685

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer